Evidence map›Paper›PMID 36052502›Full record

ArticleCancer discovery2022

Why ARNT Prostate Tumors Responding to Enzalutamide?

Meng Zhang, Thaidy Moreno-Rodriguez, David A Quigley

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Meng Zhang *Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.ORCID 0000-0003-1042-6294
Thaidy Moreno-Rodriguez *Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.ORCID 0000-0003-3588-3889
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.ORCID 0000-0002-4726-1473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryProstate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).

Indexed as

AndrogensProstatic Neoplasms, Castration-ResistantAryl Hydrocarbon Receptor Nuclear TranslocatorBenzamidesCircadian RhythmDrug Resistance, NeoplasmEpigenomicsHumansMaleNitrilesPhenylthiohydantoinReceptors, AndrogenAndrogensARNT protein, humanAryl Hydrocarbon Receptor Nuclear TranslocatorBenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgen

Identifiers

PMID36052502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.